(EXEL) Exelixis - Overview
Stock: Cancer, Medicines, Tablets, Capsules, Inhibitors
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 40.4% |
| Relative Tail Risk | -20.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.73 |
| Alpha | 19.69 |
| Character TTM | |
|---|---|
| Beta | 0.611 |
| Beta Downside | 0.248 |
| Drawdowns 3y | |
|---|---|
| Max DD | 25.34% |
| CAGR/Max DD | 1.43 |
Description: EXEL Exelixis January 02, 2026
Exelixis, Inc. (NASDAQ:EXEL) is a U.S.–focused oncology biotech that commercializes cabozantinib-based therapies-CABOMETYX for advanced renal cell carcinoma (RCC) post-anti-angiogenic treatment and COMETRIQ for progressive/metastatic medullary thyroid cancer-while maintaining a broader pipeline of kinase inhibitors, an ADC (XB010), and a MEK inhibitor combination (COTELLIC). All marketed products share the same core molecule, cabozantinib, which blocks MET, AXL, RET, and VEGF receptors.
Beyond its approved drugs, Exelixis is advancing several late-stage candidates: zanzalintinib (next-gen TKI targeting VEGF, MET, and TAM kinases), XL309 (USP1 inhibitor for BRCA-mutated tumors), and XL495 (PKMYT1 inhibitor). The firm leverages a network of collaborations with major pharma-Roche, Takeda, Merck, Bristol-Myers Squibb, among others-to share development risk and accelerate market entry. As of FY 2023, CABOMETYX generated roughly 70 % of the company’s $1.5 billion total revenue, and COMETRIQ contributed an additional $150 million, underscoring the cash-flow reliance on a narrow product set.
Sector-level drivers that materially affect Exelixis include the expanding global RCC market (projected CAGR ≈ 6 % through 2028) and the broader biotech trend of increasing R&D intensity, with industry-average R&D spend now exceeding 20 % of sales. Exelixis’ 2024 guidance assumes a 5-6 % growth in CABOMETYX sales, contingent on maintaining market share against emerging TKIs and on the successful regulatory filing of zanzalintinib. For a deeper dive into how these dynamics translate into valuation metrics, a quick look at ValueRay’s analyst toolkit may be worthwhile.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 677.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.27 > 0.02 and ΔFCF/TA 12.99 > 1.0 |
| NWC/Revenue: 44.95% < 20% (prev 55.50%; Δ -10.56% < -1%) |
| CFO/TA 0.28 > 3% & CFO 791.0m > Net Income 677.9m |
| Net Debt (-199.8m) to EBITDA (862.9m): -0.23 < 3 |
| Current Ratio: 3.75 > 1.5 & < 3 |
| Outstanding Shares: last quarter (278.5m) vs 12m ago -4.44% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 79.12% > 50% (prev 70.32%; Δ 8.81% > 0%) |
| Interest Coverage Ratio: -20.75 > 6 (EBITDA TTM 862.9m / Interest Expense TTM -40.1m) |
Altman Z'' 4.04
| A: 0.36 (Total Current Assets 1.40b - Total Current Liabilities 373.8m) / Total Assets 2.82b |
| B: -0.04 (Retained Earnings -106.1m / Total Assets 2.82b) |
| C: 0.29 (EBIT TTM 833.1m / Avg Total Assets 2.89b) |
| D: -0.15 (Book Value of Equity -102.2m / Total Liabilities 662.8m) |
| Altman-Z'' Score: 4.04 = AA |
Beneish M -2.86
| DSRI: 1.04 (Receivables 309.7m/269.7m, Revenue 2.29b/2.08b) |
| GMI: 1.00 (GM 96.63% / 96.25%) |
| AQI: 1.18 (AQ_t 0.38 / AQ_t-1 0.32) |
| SGI: 1.10 (Revenue 2.29b / 2.08b) |
| TATA: -0.04 (NI 677.9m - CFO 791.0m) / TA 2.82b) |
| Beneish M-Score: -2.86 (Cap -4..+1) = A |
What is the price of EXEL shares?
Over the past week, the price has changed by +6.14%, over one month by +0.50%, over three months by +7.60% and over the past year by +30.38%.
Is EXEL a buy, sell or hold?
- StrongBuy: 7
- Buy: 4
- Hold: 9
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the EXEL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 45.8 | 4.4% |
| Analysts Target Price | 45.8 | 4.4% |
| ValueRay Target Price | 54.3 | 23.6% |
EXEL Fundamental Data Overview February 05, 2026
P/E Forward = 13.3511
P/S = 5.0106
P/B = 5.1328
P/EG = 2.2685
Revenue TTM = 2.29b USD
EBIT TTM = 833.1m USD
EBITDA TTM = 862.9m USD
Long Term Debt = 176.5m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 25.0m USD (from shortTermDebt, last fiscal year)
Debt = 176.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -199.8m USD (from netDebt column, last quarter)
Enterprise Value = 10.65b USD (11.47b + Debt 176.5m - CCE 988.5m)
Interest Coverage Ratio = -20.75 (Ebit TTM 833.1m / Interest Expense TTM -40.1m)
EV/FCF = 14.15x (Enterprise Value 10.65b / FCF TTM 753.1m)
FCF Yield = 7.07% (FCF TTM 753.1m / Enterprise Value 10.65b)
FCF Margin = 32.91% (FCF TTM 753.1m / Revenue TTM 2.29b)
Net Margin = 29.63% (Net Income TTM 677.9m / Revenue TTM 2.29b)
Gross Margin = unknown ((Revenue TTM 2.29b - Cost of Revenue TTM 77.2m) / Revenue TTM)
Tobins Q-Ratio = 3.77 (Enterprise Value 10.65b / Total Assets 2.82b)
Interest Expense / Debt = 14.91% (Interest Expense 26.3m / Debt 176.5m)
Taxrate = 23.31% (58.8m / 252.4m)
NOPAT = 638.9m (EBIT 833.1m * (1 - 23.31%))
Current Ratio = 3.75 (Total Current Assets 1.40b / Total Current Liabilities 373.8m)
Debt / Equity = 0.08 (Debt 176.5m / totalStockholderEquity, last quarter 2.16b)
Debt / EBITDA = -0.23 (Net Debt -199.8m / EBITDA 862.9m)
Debt / FCF = -0.27 (Net Debt -199.8m / FCF TTM 753.1m)
Total Stockholder Equity = 2.14b (last 4 quarters mean from totalStockholderEquity)
RoA = 23.44% (Net Income 677.9m / Total Assets 2.82b)
RoE = 31.64% (Net Income TTM 677.9m / Total Stockholder Equity 2.14b)
RoCE = 35.93% (EBIT 833.1m / Capital Employed (Equity 2.14b + L.T.Debt 176.5m))
RoIC = 29.82% (NOPAT 638.9m / Invested Capital 2.14b)
WACC = 8.22% (E(11.47b)/V(11.64b) * Re(8.17%) + D(176.5m)/V(11.64b) * Rd(14.91%) * (1-Tc(0.23)))
Discount Rate = 8.17% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -5.67%
[DCF Debug] Terminal Value 79.26% ; FCFF base≈613.8m ; Y1≈705.8m ; Y5≈988.2m
Fair Price DCF = 61.35 (EV 16.25b - Net Debt -199.8m = Equity 16.45b / Shares 268.1m; r=8.22% [WACC]; 5y FCF grow 17.57% → 2.90% )
EPS Correlation: 53.50 | EPS CAGR: -24.31% | SUE: -4.0 | # QB: 0
Revenue Correlation: 84.14 | Revenue CAGR: 7.79% | SUE: 0.04 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.76 | Chg30d=+0.062 | Revisions Net=+0 | Analysts=4
EPS next Year (2026-12-31): EPS=3.43 | Chg30d=+0.147 | Revisions Net=+2 | Growth EPS=+15.8% | Growth Revenue=+11.9%